BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26843057)

  • 1. Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.
    Hassett MJ; Jiang W; Habel LA; Nekhlyudov L; Achacoso N; Acton L; Schnitt SJ; Schrag D; Punglia RS
    Breast Cancer Res Treat; 2016 Feb; 155(3):541-9. PubMed ID: 26843057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ.
    Arvold ND; Punglia RS; Hughes ME; Jiang W; Edge SB; Javid SH; Laronga C; Niland JC; Theriault RL; Weeks JC; Wong YN; Lee SJ; Hassett MJ
    Cancer; 2012 Dec; 118(24):6022-30. PubMed ID: 22674478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
    Rakovitch E; Nofech-Mozes S; Hanna W; Baehner FL; Saskin R; Butler SM; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Robertson SJ; Slodkowska E; Fong C; Anderson JM; Jamshidian F; Miller DP; Cherbavaz DB; Shak S; Paszat L
    Breast Cancer Res Treat; 2015 Jul; 152(2):389-98. PubMed ID: 26119102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
    Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
    Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
    Kerlikowske K; Molinaro A; Cha I; Ljung BM; Ernster VL; Stewart K; Chew K; Moore DH; Waldman F
    J Natl Cancer Inst; 2003 Nov; 95(22):1692-702. PubMed ID: 14625260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
    Rakovitch E; Nofech-Mozes S; Narod SA; Hanna W; Thiruchelvam D; Saskin R; Taylor C; Tuck A; Sengupta S; Elavathil L; Jani PA; Done SJ; Miller N; Youngson B; Kong I; Paszat L
    Breast Cancer Res Treat; 2013 Apr; 138(2):581-90. PubMed ID: 23456231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.
    Warren JL; Weaver DL; Bocklage T; Key CR; Platz CE; Cronin KA; Ballard-Barbash R; Willey SC; Harlan LC
    Cancer; 2005 Nov; 104(9):1840-8. PubMed ID: 16136599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Pawloski KR; Tadros AB; Sevilimedu V; Newman A; Gentile L; Zabor EC; Morrow M; Van Zee KJ; Kirstein LJ
    Breast Cancer Res Treat; 2021 Apr; 186(3):617-624. PubMed ID: 33675490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
    Schmitz RSJM; van den Belt-Dusebout AW; Clements K; Ren Y; Cresta C; Timbres J; Liu YH; Byng D; Lynch T; Menegaz BA; Collyar D; Hyslop T; Thomas S; Love JK; Schaapveld M; Bhattacharjee P; Ryser MD; Sawyer E; Hwang ES; Thompson A; Wesseling J; Lips EH; Schmidt MK;
    BMJ; 2023 Oct; 383():e076022. PubMed ID: 37903527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
    Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.
    Subhedar P; Olcese C; Patil S; Morrow M; Van Zee KJ
    Ann Surg Oncol; 2015 Oct; 22(10):3273-81. PubMed ID: 26215193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
    Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ.
    Tamura N; Tsuda H; Yoshida M; Hojo T; Akashi-Tanaka S; Kinoshita T; Sugihara K
    Breast Cancer; 2016 May; 23(3):510-8. PubMed ID: 25666939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and Ethnic Disparities in Rates of Invasive Second Breast Cancer Among Women With Ductal Carcinoma In Situ in Hawai'i.
    Taparra K; Fukui J; Killeen J; Sumida K; Loo LWM; Hernandez BY
    JAMA Netw Open; 2021 Oct; 4(10):e2128977. PubMed ID: 34668945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
    Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
    Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years.
    Wadsten C; Heyman H; Holmqvist M; Ahlgren J; Lambe M; Sund M; Wärnberg F
    Acta Oncol; 2016 Nov; 55(11):1338-1343. PubMed ID: 27548561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.